DRRX - DURECT Corporation

NasdaqGM - NasdaqGM Real-time price. Currency in USD
-0.03 (-1.40%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous close2.47
Bid2.10 x 1400
Ask2.11 x 3400
Day's range2.04 - 2.19
52-week range0.74 - 2.55
Avg. volume931,600
Market cap323.541M
PE ratio (TTM)N/A
EPS (TTM)-0.03
Earnings date8 May 2018 - 14 May 2018
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target est2.37
Trade prices are not sourced from all markets
  • Associated Press2 months ago

    Durect tops 4Q revenue forecasts

    On a per-share basis, the Cupertino, California-based company said it had net income of 5 cents. The specialty pharmaceutical company posted revenue of $19.5 million in the period, which topped Street ...

  • Marketwired6 months ago

    Streetwise Reports Examines Small Biotech That Entered Patent Deal with British Company Targeting Schizophrenia

    A small-cap American biotech has secured a patent agreement with a larger British firm, garnering the attention of three sector analysts.Included in this article is: DURECT Corp. In an Oct. 2 press release, ...

  • Reuters - UK Focuslast year

    NASH: The next untapped pharma market gives investors many options

    Large drugmakers with piles of cash are on the hunt for promising medicines being developed by small companies to treat NASH, a progressive fatty liver disease poised to become the leading cause of liver transplants by 2020. With (Other OTC: WWTH - news) intense competition and pricing pressure eroding sales of medicines for diabetes, rheumatoid arthritis and other lucrative disease categories, and an already crowded field for developmental cancer drugs, big pharma sees NASH as an enormous new market for future profit that will accelerate a wave of deal making. Bristol-Myers Squibb also confirmed it is looking for additional assets to enhance its internally-developed NASH drugs.

By using Yahoo you agree that Yahoo and partners may use Cookies for personalisation and other purposes